| Dr Brian Adam Davis, MD | |
|
8930 W Sunset Rd Ste 140, Las Vegas, NV 89148-5009 | |
| (702) 968-3240 | |
| (702) 862-8227 |
| Full Name | Dr Brian Adam Davis |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 32 Years |
| Location | 8930 W Sunset Rd Ste 140, Las Vegas, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760463830 | NPI | - | NPPES |
| 20169 | Other | NV | STATE LICENSE |
| 00G853930 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | G85393 (California) | Secondary |
| 2081S0010X | Physical Medicine & Rehabilitation - Sports Medicine | 20169 (Nevada) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Medical Holdings Nevada Inc | 7416054622 | 286 |
News Archive
The University of Texas at Arlington received more than $2.1 million in grants from the Cancer Prevention & Research Institute of Texas to support the University's flourishing cancer research programs.
BGS Beta-Gamma-Service, the German market leader for radiation sterilization, is set to expand its activities in the UK and will promote its services for the first time at Health GB Manchester from 30 April to 2 May.
Proscia Inc., a data solutions provider for digital pathology, announced today the completion of its $1M seed round of financing.
Nektar Therapeutics today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian cancer. A total of 68 patients were enrolled with platinum-resistant disease, half of whom were platinum refractory. All 68 patients were evaluable for the primary endpoint of objective response rate using Gynecologic Cancer InterGroup criteria, which is a combination of response by tumor imaging (RECIST) and/or ovarian cancer biomarker (CA-125) criteria.
Since the advent of pars plana vitrectomy, immense technical advances in the treatment of retinal diseases have been made. However, some mechanically based limitations of vitreoretinal surgery may result in incomplete removal of the vitreous, especially at the vitreoretinal interface and at the vitreous base. Here, pharmacology can be of assistance. For instance, enzymes that cleave the vitreoretinal junction without damaging the retina or which induce liquefaction may be applied.
› Verified 3 days ago
| Entity Name | Healthcare Partners Medical Group Coats Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487631917 PECOS PAC ID: 5991866303 Enrollment ID: O20100113000898 |
News Archive
The University of Texas at Arlington received more than $2.1 million in grants from the Cancer Prevention & Research Institute of Texas to support the University's flourishing cancer research programs.
BGS Beta-Gamma-Service, the German market leader for radiation sterilization, is set to expand its activities in the UK and will promote its services for the first time at Health GB Manchester from 30 April to 2 May.
Proscia Inc., a data solutions provider for digital pathology, announced today the completion of its $1M seed round of financing.
Nektar Therapeutics today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian cancer. A total of 68 patients were enrolled with platinum-resistant disease, half of whom were platinum refractory. All 68 patients were evaluable for the primary endpoint of objective response rate using Gynecologic Cancer InterGroup criteria, which is a combination of response by tumor imaging (RECIST) and/or ovarian cancer biomarker (CA-125) criteria.
Since the advent of pars plana vitrectomy, immense technical advances in the treatment of retinal diseases have been made. However, some mechanically based limitations of vitreoretinal surgery may result in incomplete removal of the vitreous, especially at the vitreoretinal interface and at the vitreous base. Here, pharmacology can be of assistance. For instance, enzymes that cleave the vitreoretinal junction without damaging the retina or which induce liquefaction may be applied.
› Verified 3 days ago
| Entity Name | Intermountain Medical Holdings Nevada Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245997279 PECOS PAC ID: 7416054622 Enrollment ID: O20220214001765 |
News Archive
The University of Texas at Arlington received more than $2.1 million in grants from the Cancer Prevention & Research Institute of Texas to support the University's flourishing cancer research programs.
BGS Beta-Gamma-Service, the German market leader for radiation sterilization, is set to expand its activities in the UK and will promote its services for the first time at Health GB Manchester from 30 April to 2 May.
Proscia Inc., a data solutions provider for digital pathology, announced today the completion of its $1M seed round of financing.
Nektar Therapeutics today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian cancer. A total of 68 patients were enrolled with platinum-resistant disease, half of whom were platinum refractory. All 68 patients were evaluable for the primary endpoint of objective response rate using Gynecologic Cancer InterGroup criteria, which is a combination of response by tumor imaging (RECIST) and/or ovarian cancer biomarker (CA-125) criteria.
Since the advent of pars plana vitrectomy, immense technical advances in the treatment of retinal diseases have been made. However, some mechanically based limitations of vitreoretinal surgery may result in incomplete removal of the vitreous, especially at the vitreoretinal interface and at the vitreous base. Here, pharmacology can be of assistance. For instance, enzymes that cleave the vitreoretinal junction without damaging the retina or which induce liquefaction may be applied.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brian Adam Davis, MD 6355 S Buffalo Dr Fl 3, Las Vegas, NV 89113-2133 Ph: (702) 216-3346 | Dr Brian Adam Davis, MD 8930 W Sunset Rd Ste 140, Las Vegas, NV 89148-5009 Ph: (702) 968-3240 |
News Archive
The University of Texas at Arlington received more than $2.1 million in grants from the Cancer Prevention & Research Institute of Texas to support the University's flourishing cancer research programs.
BGS Beta-Gamma-Service, the German market leader for radiation sterilization, is set to expand its activities in the UK and will promote its services for the first time at Health GB Manchester from 30 April to 2 May.
Proscia Inc., a data solutions provider for digital pathology, announced today the completion of its $1M seed round of financing.
Nektar Therapeutics today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian cancer. A total of 68 patients were enrolled with platinum-resistant disease, half of whom were platinum refractory. All 68 patients were evaluable for the primary endpoint of objective response rate using Gynecologic Cancer InterGroup criteria, which is a combination of response by tumor imaging (RECIST) and/or ovarian cancer biomarker (CA-125) criteria.
Since the advent of pars plana vitrectomy, immense technical advances in the treatment of retinal diseases have been made. However, some mechanically based limitations of vitreoretinal surgery may result in incomplete removal of the vitreous, especially at the vitreoretinal interface and at the vitreous base. Here, pharmacology can be of assistance. For instance, enzymes that cleave the vitreoretinal junction without damaging the retina or which induce liquefaction may be applied.
› Verified 3 days ago
Karlo B Arciaga, DPT Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 6440 Medical Center St Ste 100, Las Vegas, NV 89148 Phone: 702-222-1000 Fax: 702-222-9448 | |
Dr. Michael D. Digregorio, M.D. Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 6441 N Durango Dr Ste 130, Las Vegas, NV 89149 Phone: 702-538-9100 Fax: 702-478-6013 | |
Dr. Rebecca Sussman Patel, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 7251 W Lake Mead Blvd Ste 300, Las Vegas, NV 89128 Phone: 702-629-6992 Fax: 702-441-6105 | |
Ricardo Everardo Franco, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 5351 Montessouri St, Las Vegas, NV 89113 Phone: 702-251-2200 | |
Dr. David J Oliveri, M.D. Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 851 S Rampart Blvd, Suite 115, Las Vegas, NV 89145 Phone: 702-778-9300 Fax: 702-778-9301 | |
Jamie Jiao, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 851 S Rampart Blvd Ste 100, Las Vegas, NV 89145 Phone: 702-879-2005 | |
Dr. Andrea Pernell, M.D. Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 2810 W Charleston Blvd, Suite 48, Las Vegas, NV 89102 Phone: 702-870-2213 Fax: 702-870-2214 |